首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1425125

單純皰疹病毒治療的全球市場：預測（2024-2029）

Herpes Simplex Virus Treatment Market - Forecasts from 2024 to 2029

出版日期: 2024年01月29日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球單純皰疹病毒治療市場規模預計在預測期內將以 4.12% 的複合年成長率成長。

皰疹，也稱為單純皰疹病毒 (HSV)，是一種引起疼痛的水痘和潰瘍的常見疾病。口唇皰疹和單純皰疹是由 1 型 (HSV-1) 引起的兩種常見疾病，主要透過口腔接觸傳播。大多數人感染了 HSV-1。生殖器皰疹由 2 型 (HSV-2) 引起，透過性交傳播。當口唇皰疹或生殖器皰疹症狀再次出現時，您可能會感到不安。此外，生殖器皰疹還會影響性關係並造成尷尬。

單純皰疹病毒治療市場的成長動力

單純皰疹病毒（HSV）感染頻率的增加、抗病毒藥物的可用性增加以及抗病毒抗藥性的增加是推動單純皰疹病毒治療行業擴張的一些因素。研究和診斷技術的發展，以及作為預防措施的疫苗和局部殺菌劑的開發，進一步推動單純皰疹病毒治療市場的擴張。由於多種因素，HSV 治療市場正在擴大，包括患者意識的提高、遠端醫療醫療和數位醫療的採用、人口變化、持續的研發計劃以及開發中國家單純皰疹病毒治療市場的擴大。

單純皰疹病毒的傳播

根據世界衛生組織（WHO）2023年4月發布的估計，全球50歲以下的人有37億人感染口唇皰疹。67% ）被認為受到影響。單純皰疹病毒 2 型 (HSV-2) 感染是生殖器皰疹的主要原因，影響著全世界 15 至 49 歲的估計 4.91 億 (13%) 人。大多數皰疹感染是無症狀或未確診的，但疼痛的水痘和潰瘍是皰疹的症狀。感染 HSV-2 的人感染和傳播 HIV 的風險增加。

越來越重視單純皰疹病毒治療

人們對治療藥物潛力的認知不斷提高，推動了單純皰疹病毒治療市場的發展。新發或復發的皰疹感染通常用藥物治療。藥物不能消除疾病，但可以減輕其嚴重程度和持續時間。復發性發作的治療最好在症狀出現後 48 小時內開始。常用的抗病毒藥物包括伐昔洛韋、泛昔洛韋和阿昔洛韋。通常建議患有劇烈疼痛、頻繁發作或希望降低將皰疹傳播給他人的風險的人接受治療。治療疼痛的藥物包括Ibuprofen、萘普生和乙醯胺酚（對乙醯胺酚）。可以使用利多卡因或Benzocaine因等藥物來麻醉受影響的區域。

加大研發力度

由於單純皰疹病毒 (HSV)感染疾病的慢性性、高發病率和病毒潛伏期，HSV 治療的研究和開發至關重要。對潛伏病毒持有、抗病毒抗藥性以及更有效的抗病毒藥物的開發的研究正在進行中。最近的研究表明，HSV 複製需要特定的週期蛋白依賴型激酶(CDKS)。藥物 CDK 抑制劑 (PCI) 可以透過多種方式阻斷 HSV-1 感染。 PCI 阻斷病毒 DNA 產生和基因表現的即時和早期刺激。

病毒學檢測的普及

由於 HSV 可以在陰道潰瘍和其他黏膜病變中檢測到，因此 HSV NAAT 檢測是最敏感的診斷方法，並且變得越來越可用。 FDA 批准了多種 HSV 檢測測試，靈敏度範圍為 90.9% 至 100%。中樞神經系統 (CNS) 疾病和全身性疾病（腦膜炎、腦炎、新生兒皰疹等）也最常使用 PCR 檢測進行診斷。然而，血液中的 HSV PCR 檢測不應用於檢測生殖器皰疹感染，除非有廣泛感染的風險（例如肝炎）。在這種情況下，唯一的病毒學測試是病毒培養。

改進診斷技術

診斷技術的進步永遠改變了單純皰疹病毒 (HSV) 檢測和治療的準確性和有效性。聚合酵素鏈鎖反應(PCR) 測試可提供快速、準確的觀察，包括有助於早期診斷和開始治療的照護現場解決方案。血清學檢測可揭示患者的感染史，基因序列測定可揭示病毒的類型以及可能對抗病毒藥物的抗藥性。微流體和生物感測器是新興技術的例子，可以實現更快、更便宜的診斷。

北美單純皰疹病毒治療市場預計穩定成長

阿昔洛韋、伐昔洛韋和泛昔洛韋等抗病毒藥物主導著北美單純皰疹病毒治療市場。這些藥物旨在抑制和緩解 HSV-1 和 HSV-2 的症狀。 HSV-1 和 HSV-2感染疾病的抑制治療包括每天服用抗病毒藥物，以減少 HSV-1 和 HSV-2感染疾病。-1/HSV-2 用於治療感染疾病發生時的症狀。為了降低感染風險，必須採取預防措施，例如安全性行為以及與伴侶討論您的 HSV 狀況。

單純皰疹病毒治療臨床試驗

2023 年 9 月，美國衛生研究院宣布了單純皰疹病毒研究策略計劃，以解決單純皰疹病毒 1 (HSV-1) 和 HSV-2 帶來的持續健康風險。
根據 BioNTech SE 發布的聲明，2022 年 12 月，單純皰疹病毒（HSV）候選疫苗 BNT163 將在首次人體試驗中進行測試，用於預防由 HSV-2 和可能的 HSV-1 引起的陰道病變。是在一個分階段的臨床研究計劃中進行的。本研究 (NCT05432583) 評估了 BNT163 的免疫抗原性、安全性和耐受性。

Herpes, also known as herpes simplex virus (HSV), is a common illness that can result in painful blisters or ulcers. Oral herpes and cold sores are two common illnesses caused by Type 1 (HSV-1) that are mostly transmitted through oral contact. The majority of people have HSV-1 infection. Genital herpes is caused by type 2 (HSV-2) and is transmitted during intercourse. It might be upsetting to experience recurrent oral or genital herpes symptoms. Additionally, genital herpes may affect sexual relationships and be stigmatizing.

Growth drivers for Herpes Simplex Virus Treatment Market

The increased frequency of herpes simplex virus (HSV) infections, the accessibility of antiviral drugs, and the rise in antiviral resistance are some of the factors propelling the expansion of the herpes simplex virus treatment industry. Further driving herpes simplex virus treatment market expansion are technological developments in research and diagnostics, as well as the creation of vaccines and topical microbicides as preventative measures. The market for HSV therapy is expanding due to several factors, including rising patient awareness, the incorporation of telemedicine and digital health, shifting demographics, continuous research and development initiatives, and herpes simplex virus treatment market expansion in developing nations.

Growing prevalence of herpes simplex virus

As per the World Health Organization estimates published in April 2023, the primary source of oral herpes, herpes simplex virus type 1 (HSV-1) infection, is thought to affect 3.7 billion persons under 50 (67%) worldwide. The primary cause of genital herpes, herpes simplex virus type 2 (HSV-2) infection, affects an estimated 491 million persons aged 15 to 49 globally (13%). The majority of herpes infections are asymptomatic or go undiagnosed, but painful blisters or ulcers that might eventually reoccur are signs of herpes. The risk of contracting and spreading HIV infection is elevated in individuals with HSV-2 infection.

Increasing emphasis on herpes simplex virus treatment

The growing awareness of possible medications for the treatment is fueling the herpes simplex virus treatment market. First-time or recurring herpes outbreaks are frequently treated with medications. They cannot eliminate the illness, but they can lessen its severity and duration. When treatment for recurring episodes is initiated within 48 hours of the onset of symptoms, the best results are achieved. Commonly prescribed antiviral medications include valacyclovir, famciclovir, and acyclovir. Those who have excruciating pain or recurring outbreaks often, or who wish to reduce their risk of spreading herpes to others, are frequently advised to seek treatment. Medication for soreness pain management includes ibuprofen, naproxen, and paracetamol (acetaminophen). Medications such as lidocaine and benzocaine might be used to numb the afflicted region.

Increasing R&D initiatives

The chronic nature, broad incidence, and viral latency of herpes simplex virus (HSV) infections make research and development (R&D) efforts for HSV therapy imperative. Research into latent virus reservoirs, antiviral resistance, and the development of more potent antiviral medications are all ongoing. Recent research studies have shown that HSV replication requires certain cyclin-dependent kinases (CDKS). There are many ways that pharmacological CDK inhibitors (PCIs) might stop HSV-1 infection. The PCIs halt the production of viral DNA and the immediate, and early stimulation of gene expression.

Growing utilization of virologic tests

Since HSV may be detected from vaginal ulcers or other mucocutaneous lesions, HSV NAAT assays are the most sensitive diagnostics; they are becoming more and more accessible. Although there are several FDA-cleared assays for HSV detection, their sensitivity ranges from 90.9% to 100%. Diseases of the central nervous system (CNS) and systemic diseases (such as meningitis, encephalitis, and newborn herpes) are also best diagnosed by PCR. However, blood HSV PCR testing should not be used to detect genital herpes infections unless there is a risk of a widespread infection (for example, hepatitis). In these situations, the sole virologic test available is viral culture.

Improvement in diagnostic technologies

The accuracy and efficacy of herpes simplex virus (HSV) detection and therapy have been completely transformed by developments in diagnostic technology. Rapid and accurate findings are provided by polymerase chain reaction (PCR) testing, including point-of-care solutions, which help with early diagnosis and treatment commencement. The history of a patient's exposure is established by serological testing, and the types of viruses and possible resistance to antivirals are revealed by genetic sequencing methods. Microfluidics and biosensors are examples of emerging technologies that show promise for even quicker and more affordable diagnostics.

The herpes simplex virus treatment market in the North American region is anticipated to grow steadily.

Antiviral drugs, such as acyclovir, valacyclovir, and famciclovir, are the mainstay of the herpes simplex virus treatment market in North America. These drugs are intended to control and lessen the symptoms of HSV-1 and HSV-2. While suppressive therapy entails taking antiviral medicine every day to lessen the frequency and severity of recurring outbreaks, episodic therapy is used to treat symptoms during outbreaks. Reducing the risk of transmission requires preventive measures, such as safe sexual practices and talking to partners about HSV status.

Herpes Simplex Virus Treatment Clinical Trials

In September 2023, the National Institutes of Health unveiled the Strategic Plan for Herpes Simplex Virus Research in response to the ongoing health risks posed by herpes simplex virus 1 (HSV-1) and HSV-2. The strategy was prepared by an NIH-wide HSV Working Group, which took into account input from over 100 members of the advocacy and scientific sectors as well as interested public stakeholders.
In December 2022, BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of vaginal lesions caused by HSV-2 and maybe HSV-1, was dosed to the first patient in a first-in-human Phase 1 clinical research project, according to a statement released by BioNTech SE. The trial (NCT05432583) assessed BNT163's immunogenicity, safety, and tolerability.

Market Key Developments

In May 2023, Vyjuvek, a herpes simplex virus type 1 (HSV-1) vector-based gene therapy, was approved by the U.S. Food and Drug Administration to treat wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene and are at least six months of age.
In February 2023, CIBINQO® (abrocitinib) had a broader indication as the FDA approved Pfizer Inc.'s supplemental New Drug Application (sNDA). This allows adolescents (12 to <18 years old) with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is not advised.

Segmentation:

By Treatment

Herpes Simplex Virus-1
Herpes Simplex Virus-2

By Drug

Acyclovir
Valacyclovir
Famciclovir
Others

By End-User

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. HERPES SIMPLEX VIRUS TREATMENT MARKET BY TREATMENT

5.1. Introduction
5.2. Herpes Simplex Virus-1
5.3. Herpes Simplex Virus-2

6. HERPES SIMPLEX VIRUS TREATMENT MARKET BY DRUG

6.1. Introduction
6.2. Acyclovir
6.3. Valacyclovir
6.4. Famciclovir
6.5. Others

7. HERPES SIMPLEX VIRUS TREATMENT MARKET BY END-USER

7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Online Pharmacy

8. HERPES SIMPLEX VIRUS TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others